The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.
 
Marine Gross-Goupil
Consulting or Advisory Role - Amgen; amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Research Funding - Astrazeneca (Inst); Astrazeneca (Inst); BMS (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; ipsen; ipsen; ipsen; Ipsen; Janssen-Cilag; MSD Oncology; MSD Oncology; pfizer; Pfizer; Roche
Other Relationship - Janssen
 
Felix Lefort
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Eisai; Eisai; ipsen; ipsen; Janssen; Merck; Merck; MSD; Pfizer
 
Mathieu Larroquette
No Relationships to Disclose
 
Julien Asselineau
No Relationships to Disclose
 
Eric Frison
No Relationships to Disclose
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer
 
Alain Ravaud
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Merck KGaA; MSD Oncology; MSD Oncology; Pfizer
Research Funding - Ipsen (Inst); Merck KGaA (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; ipsen; MSD; Pfizer